Treatment of Primary CNS Germinomas
- Biopsy when diagnosis in question: The initial approach is to perform a biopsy +/- CSF diversion procedure only if the diagnosis cannot be made on serum or CSF tumor markers alone.
- 25% relapse with radiotherapy alone: Traditionally, germinomas were treated with radiation alone as they are exquisitely sensitive to it. Germinomas are also very sensitive to chemotherapy; however, 25% of patients relapse if the chemotherapy is not followed with radiation (57).
- Pretreatment with chemotherapy reduces radiation dose: Although germinomas can be cured with radiation alone, the current trend is to treat with chemotherapy first with the expectation that a complete response will be induced. This will allow a reduction in the dose of radiation and thus a reduction in the long-term side effects of radiation. Two to four cycles of carboplatin- and etoposide- based therapy are usual for germinomas. In the absence of dissemination at diagnosis, current trends are toward whole ventricular radiation after a complete response to chemotherapy with or without resection (58, 59, 63).
- Resect residual tumor after chemotherapy: The resection is followed by induction chemotherapy. If the tumor grows or if there is a surgically amenable residual mass with normalization of tumor markers, then resection is considered to remove the likely teratoma component.
SIOP CNS protocol 96 (63)
- Days 1–3 and 43–45: Carboplatin, 600 mg/m²/day IV; etoposide, 100 mg/m²/day IV
- Days 22–27 and 64–69: Etoposide, 100 mg/m²/day IV; ifosfamide, 1800 mg/m²/day IV
Treatment of Malignant CNS Germ Cell Tumors
- Serum and CSF markers diagnostic: Malignant CNS germ cell tumors are diagnosed on the basis of tumor markers in serum and CSF.
- Combined radiation therapy and chemotherapy: Malignant CNS germ cell tumors are more aggressive and require more intense chemotherapy than germinomas (60). They also are highly responsive to chemotherapy; however, a relapse rate of 70% is observed if chemotherapy is not followed by radiation therapy (57). Radiation therapy alone also has a low cure rate. Radiation therapy is usually 36 Gy craniospinal (62); however, present clinical trials are exploring the possibility of whole ventricular radiation in those with localized disease at diagnosis.
- Surgery for residual after chemotherapy: Second-look surgery is considered for growing teratoma syndrome (61) or surgically amenable residual disease prior to radiation.
Induction chemotherapy – four 28-day cycles (64)
- Days 1–5: Cisplatin, 20 mg/m²/day IV
- Days 1–5: Etoposide, 75 mg/m²/ day IV
- Days 1–5: Ifosfamide, 1.2 g/ m²/ day IV
Dose intensification chemotherapy for residual disease
Two cycles with each cycle having a duration of 21 days are used if there has not been a complete response to induction chemotherapy. This regimen is coupled with blood stem cell rescue using bone marrow transplantation (64).
- Days 1–2: Cyclophosphamide, 2 g/m²/day IV
- Days 1–3: Carboplatin, 400 mg/m²/day IV
- Bone marrow rescue: Infusion of >2 x 106 CD 34 stem cells 48–72 hours after completion of chemotherapy
- Germinoma 5-year survival rate near 100%: Localized germinomas treated with multimodality therapy have a 5-year EFS rate of 88% and an OS rate of 96% (63).
- Malignant germ cell tumor 10-year survival rate 77%: Malignant germ cell tumors treated with multimodality therapy have a 10-year PFS rate of 74% and an OS rate of 77% (62).
Please create a free account or log in to read 'Chemotherapy for Primary CNS Germ Cell Tumors in Children'
Registration is free, quick and easy. Register and complete your profile and get access to the following:
- Full unrestricted access to The ISPN Guide
- Download pages as PDFs for offline viewing
- Create and manage page bookmarks
- Access to new and improved on-page references